Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy (M.G., D.S., M.M., M.D.F., A.P., G.D.A., F.B., G.S.).
Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden (D.S.).
Circulation. 2021 Nov 16;144(20):1600-1611. doi: 10.1161/CIRCULATIONAHA.121.053521. Epub 2021 Sep 30.
Filamin C truncating variants () cause a form of arrhythmogenic cardiomyopathy: the mode of presentation, natural history, and risk stratification of remain incompletely explored. We aimed to develop a risk profile for refractory heart failure and life-threatening arrhythmias in a multicenter cohort of carriers.
carriers were identified from 10 tertiary care centers for genetic cardiomyopathies. Clinical and outcome data were compiled. Composite outcomes were all-cause mortality/heart transplantation/left ventricle assist device (D/HT/LVAD), nonarrhythmic death/HT/LVAD, and sudden cardiac death/major ventricular arrhythmias. Previously established cohorts of 46 patients with and 60 with -related arrhythmogenic cardiomyopathies were used for prognostic comparison.
Eighty-five patients carrying were included (42±15 years, 53% men, 45% probands). Phenotypes were heterogeneous at presentation: 49% dilated cardiomyopathy, 25% arrhythmogenic left dominant cardiomyopathy, 3% arrhythmogenic right ventricular cardiomyopathy. Left ventricular ejection fraction was <50% in 64% of carriers and 34% had right ventricular fractional area changes (RVFAC=(right ventricular end-diastolic area - right ventricular end-systolic area)/right ventricular end-diastolic area) <35%. During follow-up (median time 61 months), 19 (22%) carriers experienced D/HT/LVAD, 13 (15%) experienced nonarrhythmic death/HT/LVAD, and 23 (27%) experienced sudden cardiac death/major ventricular arrhythmias. The sudden cardiac death/major ventricular arrhythmias incidence of carriers did not significantly differ from carriers and carriers. In carriers, left ventricular ejection fraction was associated with the risk of D/HT/LVAD and nonarrhythmic death/HT/LVAD.
Among patients referred to tertiary referral centers, arrhythmogenic cardiomyopathy is phenotypically heterogeneous and characterized by a high risk of life-threatening arrhythmias, which does not seem to be associated with the severity of left ventricular dysfunction.
细丝蛋白 C 截断变异 () 导致一种心律失常性心肌病:其表现形式、自然病史和风险分层仍不完全清楚。我们旨在为 10 个三级遗传性心肌病中心的一组 携带者制定难治性心力衰竭和危及生命的心律失常的风险特征。
从 10 个三级遗传性心肌病中心确定 携带者。收集临床和预后数据。复合结果为全因死亡率/心脏移植/左心室辅助装置(D/HT/LVAD)、非心律失常性死亡/HT/LVAD 和心脏性猝死/主要室性心律失常。先前建立的 46 例 患者和 60 例 -相关心律失常性心肌病患者的队列用于预后比较。
共纳入 85 例携带 的患者(42±15 岁,53%为男性,45%为先证者)。表型在发病时呈异质性:49%扩张型心肌病,25%心律失常性左优势型心肌病,3%心律失常性右心室心肌病。64%的携带者左心室射血分数<50%,34%的右心室分数面积变化(RVFAC=(右心室舒张末期面积-右心室收缩末期面积)/右心室舒张末期面积)<35%。在随访期间(中位数时间 61 个月),19 名(22%)携带者经历了 D/HT/LVAD,13 名(15%)经历了非心律失常性死亡/HT/LVAD,23 名(27%)经历了心脏性猝死/主要室性心律失常。携带者的心脏性猝死/主要室性心律失常发生率与 携带者和 携带者无显著差异。在 携带者中,左心室射血分数与 D/HT/LVAD 和非心律失常性死亡/HT/LVAD 的风险相关。
在转诊至三级转诊中心的患者中,心律失常性心肌病表型呈异质性,以危及生命的心律失常风险高为特征,这似乎与左心室功能障碍的严重程度无关。